Cosentino James, Zhao Huaqing, Hardin Megan, Hersh Craig P, Crapo James, Kim Victor, Criner Gerard J
1 Department of Thoracic Medicine and Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania.
2 Brigham and Women's Hospital, Boston, Massachusetts; and.
Ann Am Thorac Soc. 2016 Sep;13(9):1483-9. doi: 10.1513/AnnalsATS.201511-761OC.
Despite the increasing recognition of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) as a clinical entity, it remains poorly characterized due to a lack of agreement on its definition and diagnostic criteria.
The aim of this study was to use spirometry and computed tomography (CT) to help better define ACOS as well as to classify subjects with ACOS based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) letter grade.
We analyzed 10,192 subjects enrolled in the COPDGene Study. Subjects were non-Hispanic white or African American current or former smokers aged 45-80 years with at least a 10-pack-year smoking history. Subjects were categorized as having either ACOS with a bronchodilator response or chronic obstructive pulmonary disease with emphysema on the basis of spirometry, high-resolution CT, and a history of asthma or hay fever.
Subjects with ACOS were younger (60.6 vs. 65.9 years old; P < 0.0001), more likely to be African American (26.8% vs. 14.4%; P < 0.0001), had a higher body mass index (29.6 vs. 25.1 kg/m(2); P < 0.0001), and were more likely to be current smokers (50.9% vs. 20.7%; P < 0.0001). The majority of subjects with ACOS were categorized as GOLD grade B. Despite less severe spirometry and CT findings in subjects with ACOS, there was no significant difference in severe or frequent exacerbations.
Bronchodilator responsiveness and degree of emphysema can help define ACOS. When defined on the basis of bronchodilator responsiveness and degree of emphysema, patients with ACOS represent a unique and high-risk group with distinct clinical features.
尽管哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)作为一种临床实体越来越受到认可,但由于对其定义和诊断标准缺乏共识,其特征仍不明确。
本研究旨在利用肺功能测定和计算机断层扫描(CT)来更好地定义ACOS,并根据慢性阻塞性肺疾病全球倡议(GOLD)字母分级对ACOS患者进行分类。
我们分析了参与慢性阻塞性肺疾病基因研究(COPDGene Study)的10192名受试者。受试者为非西班牙裔白人或非裔美国人,年龄在45 - 80岁之间,目前或曾经吸烟,吸烟史至少为10包年。根据肺功能测定、高分辨率CT以及哮喘或花粉热病史,将受试者分为具有支气管扩张剂反应的ACOS患者或伴有肺气肿的慢性阻塞性肺疾病患者。
ACOS患者更年轻(60.6岁对65.9岁;P < 0.0001),更可能是非裔美国人(26.8%对14.4%;P < 0.0001),体重指数更高(29.6对25.1 kg/m²;P < 0.0001),且更可能是当前吸烟者(50.9%对20.7%;P < 0.0001)。大多数ACOS患者被分类为GOLD B级。尽管ACOS患者的肺功能测定和CT表现较轻,但严重或频繁发作方面无显著差异。
支气管扩张剂反应性和肺气肿程度有助于定义ACOS。基于支气管扩张剂反应性和肺气肿程度定义时,ACOS患者代表了一个具有独特临床特征的高危群体。